85 related articles for article (PubMed ID: 18825844)
1. Aberrant expression of CD7 in acute myeloid leukemias with FLT3-ITD.
Juncà J; Zamora L; Cabezón M; Marcè S; Nomdedéu J
Am J Clin Pathol; 2008 Oct; 130(4):644; author reply 645. PubMed ID: 18825844
[No Abstract] [Full Text] [Related]
2. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias.
Cruse JM; Lewis RE; Pierce S; Lam J; Tadros Y
Exp Mol Pathol; 2005 Aug; 79(1):39-41. PubMed ID: 16005710
[TBL] [Abstract][Full Text] [Related]
4. HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression.
Syampurnawati M; Tatsumi E; Furuta K; Takenokuchi M; Nakamachi Y; Kawano S; Kumagai S; Saigo K; Matsui T; Takahashi T; Nagai K; Yabe H; Kondo S; Hayashi Y
Leuk Res; 2007 Jul; 31(7):921-9. PubMed ID: 17056111
[TBL] [Abstract][Full Text] [Related]
5. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia.
Hoehn D; Medeiros LJ; Chen SS; Tian T; Jorgensen JL; Ahmed Y; Lin P
Am J Clin Pathol; 2012 Feb; 137(2):213-9. PubMed ID: 22261446
[TBL] [Abstract][Full Text] [Related]
6. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
Lee SH; Paietta E; Racevskis J; Wiernik PH
Am J Hematol; 2009 Oct; 84(10):701-2. PubMed ID: 19714594
[No Abstract] [Full Text] [Related]
7. Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias.
Inomata M; Takahashi S; Harigae H; Kameoka J; Kaku M; Sasaki T
Leuk Res; 2006 Jun; 30(6):659-64. PubMed ID: 16271760
[TBL] [Abstract][Full Text] [Related]
8. A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival.
Masson K; Liu T; Khan R; Sun J; Rönnstrand L
Br J Haematol; 2009 Jul; 146(2):193-202. PubMed ID: 19438505
[TBL] [Abstract][Full Text] [Related]
9. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
Jin G; Matsushita H; Asai S; Tsukamoto H; Ono R; Nosaka T; Yahata T; Takahashi S; Miyachi H
Biochem Biophys Res Commun; 2009 Dec; 390(3):1001-6. PubMed ID: 19853583
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.
Safaian NN; Czibere A; Bruns I; Fenk R; Reinecke P; Dienst A; Haas R; Kobbe G
Leuk Res; 2009 Feb; 33(2):348-50. PubMed ID: 18573526
[TBL] [Abstract][Full Text] [Related]
11. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
Spiekermann K; Hiddemann W; Schnittger S
Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
[No Abstract] [Full Text] [Related]
12. A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
Fesler MJ; Richart JM; Petruska PJ
Leuk Res; 2010 Oct; 34(10):e268-9. PubMed ID: 20417967
[No Abstract] [Full Text] [Related]
13. Molecular variability of FLT3/ITD mutants and their impact on the differentiation program of 32D cells: implications for the biological properties of AML blasts.
Pekova S; Ivanek R; Dvorak M; Rueggeberg S; Leicht S; Li X; Franz T; Kozak T; Vrba J; Koza V; Karas M; Schwarz J; Cetkovsky P; Prucha M
Leuk Res; 2009 Oct; 33(10):1409-16. PubMed ID: 19181379
[TBL] [Abstract][Full Text] [Related]
14. Cup-like acute myeloid leukemia: new disease or artificial phenomenon?
Kroschinsky FP; Schäkel U; Fischer R; Mohr B; Oelschlaegel U; Repp R; Schaich M; Soucek S; Baretton G; Ehninger G; Thiede C;
Haematologica; 2008 Feb; 93(2):283-6. PubMed ID: 18223289
[TBL] [Abstract][Full Text] [Related]
15. Images in clinical medicine. FLT3 Mutation and acute myelogenous leukemia with leukostasis.
Thornton KA; Levis M
N Engl J Med; 2007 Oct; 357(16):1639. PubMed ID: 17942876
[No Abstract] [Full Text] [Related]
16. Molecular genetics in acute myeloid leukemia.
Bacher U; Schnittger S; Haferlach T
Curr Opin Oncol; 2010 Nov; 22(6):646-55. PubMed ID: 20805748
[TBL] [Abstract][Full Text] [Related]
17. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics.
Huang Q; Chen W; Gaal KK; Slovak ML; Stein A; Weiss LM
Br J Haematol; 2008 Jul; 142(3):489-92. PubMed ID: 18477048
[No Abstract] [Full Text] [Related]
18. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
Sritana N; Auewarakul CU
Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
[TBL] [Abstract][Full Text] [Related]
19. FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype.
Ferrara F; Criscuolo C; Riccardi C; Izzo T; Pedata M; Copia C; Vicari L; Tarsitano M; Palmieri S; Pane F
Am J Hematol; 2009 Aug; 84(8):532-5. PubMed ID: 19562748
[No Abstract] [Full Text] [Related]
20. Four novel point mutations in exons 12, 13, and 14 of the FLT3 gene.
Syampurnawati M; Tatsumi E; Furuta K; Hayashi Y
Leuk Res; 2007 Jun; 31(6):877. PubMed ID: 16949153
[No Abstract] [Full Text] [Related]
[Next] [New Search]
